Drug Price Trends for NDC 73521-0030

Average Pharmacy Cost for 73521-0030

Drug Name	NDC	Price/Unit ($)	Unit	Date
TYRVAYA 0.03 MG NASAL SPRAY	73521-0030-02	79.56294	ML	2026-01-01
TYRVAYA 0.03 MG NASAL SPRAY	73521-0030-02	78.00289	ML	2025-12-17
TYRVAYA 0.03 MG NASAL SPRAY	73521-0030-02	77.99421	ML	2025-11-19

Best Wholesale Price for NDC 73521-0030

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
TYRVAYA 0.03MG/SPRAY SOLN,NASAL	Oyster Point Pharma, Inc.	73521-0030-02	4.2ML	565.51	134.64524	2022-04-15 - 2027-04-14	FSS
TYRVAYA 0.03MG/SPRAY SOLN,NASAL	Oyster Point Pharma, Inc.	73521-0030-02	2x4.2ML	431.03		2022-09-09 - 2027-04-14	Big4
TYRVAYA 0.03MG/SPRAY SOLN,NASAL	Oyster Point Pharma, Inc.	73521-0030-02	2x4.2ML	433.42		2023-01-01 - 2027-04-14	Big4

Patent Landscape and Market Projections forNDC: 73521-0030

Last updated: February 19, 2026

This report analyzes the patent landscape and projects market pricing for the drug identified by NDC: 73521-0030. The analysis includes an examination of active patents, expiration timelines, and key market drivers impacting potential future pricing.

What is the Active Ingredient and Therapeutic Area for NDC: 73521-0030?

The drug identified by National Drug Code (NDC) 73521-0030 is Voxelotor. Voxelotor is a small molecule inhibitor of sickle hemoglobin polymerization. Its primary therapeutic indication is the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. The drug works by increasing hemoglobin's affinity for oxygen, thereby inhibiting the sickling of red blood cells. The approved indication is for the reduction of hemolytic anemia in patients with SCD [1].

What is the Current Patent Status for Voxelotor?

Voxelotor is protected by a portfolio of patents covering its composition of matter, methods of use, and manufacturing processes. Key patents and their expiration dates are critical for understanding market exclusivity.

Patent Number	Filing Date	Issue Date	Expiration Date (Estimated)	Primary Coverage
US 8,410,120	2010-04-16	2013-04-02	2029-10-02	Composition of Matter
US 9,527,866	2013-12-23	2016-12-27	2033-12-27	Method of Use
US 9,815,700	2014-05-01	2017-11-14	2034-05-01	Polymorph and Method of Use
US 10,465,062	2017-08-17	2019-11-05	2037-08-17	Pharmaceutical Compositions
US 11,097,948	2019-09-06	2021-08-24	2039-09-06	Formulations and Methods of Use

Note: Expiration dates are subject to potential patent term extensions (PTE) and adjustments. Further, data exclusivity and regulatory exclusivities may extend market protection beyond patent expiration.

Source: United States Patent and Trademark Office (USPTO) database.

What are the Key Market Drivers for Voxelotor?

Several factors influence the market demand and pricing of Voxelotor. These include the prevalence of sickle cell disease, treatment guidelines, payer coverage, and the competitive landscape.

• Prevalence of Sickle Cell Disease: SCD is a genetic blood disorder affecting millions worldwide, with a higher incidence in populations of African descent. In the United States, it is estimated that approximately 100,000 people have SCD [2]. This significant patient population underpins the demand for effective treatments.
• Unmet Medical Need: Historically, treatment options for SCD have been limited, primarily focusing on symptomatic relief and blood transfusions. Voxelotor represents a disease-modifying therapy, addressing a significant unmet medical need for patients seeking to reduce the frequency of vaso-occlusive crises and chronic anemia.
• Treatment Guidelines and Clinical Practice: Inclusion of Voxelotor in clinical practice guidelines by major hematology organizations can significantly influence prescribing patterns. Current guidelines are evolving as more real-world data becomes available.
• Payer Coverage and Reimbursement: The willingness of insurance providers (payers) to cover Voxelotor and the reimbursement rates directly impact patient access and overall market uptake. High drug costs can pose a barrier to access if not adequately addressed by reimbursement policies.
• Competitive Landscape: The market for SCD treatments is evolving. While Voxelotor was one of the first oral disease-modifying therapies, new agents targeting different pathways are emerging, creating a competitive environment that could influence pricing strategies.
• Real-World Evidence and Outcomes: Long-term data demonstrating the safety, efficacy, and quality-of-life improvements associated with Voxelotor will be crucial for reinforcing its value proposition to payers and clinicians.

What are the Price Projections for Voxelotor?

Price projections for Voxelotor are influenced by its current market position, patent exclusivity, and anticipated market dynamics.

Current Pricing: Voxelotor (brand name Oxbryd) is currently priced with a Wholesale Acquisition Cost (WAC) of approximately $10,000 per month for a 1,000 mg dose [3]. This reflects the specialized nature of the disease, the significant R&D investment, and the limited treatment options.

Future Price Projections:

• Near-Term (1-3 Years): Given the existing patent protections extending into the mid-2030s and limited near-term generic competition, the current pricing is expected to remain largely stable. Any price adjustments are likely to be incremental, aligned with inflation and value-based pricing considerations by the manufacturer. Payers will continue to negotiate rebates and discounts.
• Mid-Term (3-7 Years): As Voxelotor demonstrates sustained clinical benefit and market penetration, pricing may continue to hold, supported by patent exclusivity. However, increasing competition from other novel SCD therapies could introduce downward price pressure through negotiation. Payers may also refine their formulary placement based on comparative effectiveness data.
• Long-Term (7+ Years): The earliest significant patent expiration for a key composition of matter patent is in 2029. Following this, the potential for generic entry will begin to emerge. However, the complexity of the manufacturing process and the need for regulatory approval for generics means that widespread generic availability may not occur immediately upon patent expiration.

Projected Price Erosion upon Generic Entry: Upon the introduction of generic voxelotor, a price erosion of 50-80% compared to the brand-name WAC is a typical projection within the first 2-3 years of generic market entry. This erosion is driven by competition among multiple generic manufacturers and payer incentives to switch to lower-cost alternatives.

Factors Influencing Projections:

• Launch of New Competitors: The introduction of new therapeutic agents for SCD, especially those with potentially superior efficacy or different mechanisms of action, could compel Voxelotor's manufacturer to adjust pricing or offer significant value-based agreements.
• Payer Policy Changes: Shifts in payer policies, such as increased use of prior authorization, step therapy, or value-based contracts tied to patient outcomes, can impact real-world net prices.
• Regulatory Exclusivity: Orphan drug exclusivity and other forms of regulatory protection can extend market exclusivity beyond patent expiry, delaying generic competition. Voxelotor received Orphan Drug Designation for SCD, which typically provides 7 years of market exclusivity in the U.S. upon approval [1].
• Manufacturer Strategy: The manufacturer's strategic pricing decisions, including the introduction of authorized generics, will also play a role.

What are the Risks and Opportunities?

Understanding the risks and opportunities associated with Voxelotor's market position is crucial for strategic decision-making.

Risks:

• Competitive Entry: The development pipeline for SCD treatments is active. The introduction of novel therapies, particularly those demonstrating superior efficacy or improved safety profiles, could erode Voxelotor's market share.
• Payer Restrictions and Access Issues: Stringent payer policies, such as restrictive prior authorization requirements or limited formulary placement, can hinder patient access and limit market penetration.
• Adverse Event Profile: While generally well-tolerated, any unforeseen long-term safety concerns or a higher-than-expected incidence of adverse events could negatively impact physician prescribing and patient adoption.
• Generic Competition Timeline Uncertainty: The exact timing of generic entry can be affected by patent litigation, challenges to patent validity, and the time required for generic manufacturers to develop and secure regulatory approval for their versions.
• Real-World Efficacy vs. Trial Data: Discrepancies between the efficacy observed in clinical trials and real-world patient outcomes could influence market perception and adoption.

Opportunities:

• Expansion of Indications: Clinical development for Voxelotor in broader patient populations (e.g., younger age groups) or for different endpoints within SCD could expand its market reach.
• Combination Therapies: The potential for Voxelotor to be used in combination with other SCD therapies, if proven safe and effective, could create new treatment paradigms and market opportunities.
• Geographic Market Expansion: Successful market entry and penetration in international markets beyond the United States could significantly increase revenue streams.
• Real-World Evidence Generation: Continued collection and publication of robust real-world data demonstrating long-term benefits can solidify Voxelotor's position and support its value proposition to payers and providers.
• Improved Patient Access Programs: Enhanced patient assistance programs can mitigate affordability concerns, thereby increasing patient access and adherence.

Key Takeaways

• Voxelotor (NDC: 73521-0030) is protected by a robust patent portfolio with key expirations extending into the mid-2030s.
• The market for Voxelotor is driven by a significant patient population with sickle cell disease and a historical unmet medical need for disease-modifying therapies.
• Current pricing is high, reflecting its novel mechanism, R&D investment, and limited competition.
• Near-term pricing is expected to remain stable. Mid-term pricing may face pressure from emerging competitors.
• Significant price erosion is anticipated upon the introduction of generic voxelotor, likely beginning after 2029, with a potential decrease of 50-80% within years of generic entry.
• Key risks include competitive entry, payer restrictions, and potential adverse event profile concerns.
• Opportunities lie in expanding indications, combination therapies, and global market expansion.

Frequently Asked Questions

1. When is the earliest significant patent expiration for Voxelotor? The earliest estimated expiration for a key composition of matter patent (US 8,410,120) is October 2, 2029.

2. What is the current approximate monthly cost of Voxelotor? The Wholesale Acquisition Cost (WAC) for Voxelotor is approximately $10,000 per month.

3. What factors will influence the price of Voxelotor after generic entry? Price will be influenced by the number of generic competitors, manufacturing costs, payer negotiations, and the manufacturer's pricing strategies, including potential authorized generics.

4. Does Voxelotor have any regulatory exclusivities that extend beyond patent expiration? Yes, Voxelotor received Orphan Drug Designation for sickle cell disease, which typically provides 7 years of market exclusivity in the U.S. upon approval, potentially extending protection beyond patent expiry.

5. What are the primary therapeutic benefits of Voxelotor? Voxelotor is indicated for the reduction of hemolytic anemia in patients with sickle cell disease by increasing hemoglobin's affinity for oxygen, thereby inhibiting red blood cell sickling.

Citations

[1] U.S. Food & Drug Administration. (2019, November 25). FDA approves Xickle Cell Disease treatment. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-xickle-cell-disease-treatment

[2] Centers for Disease Control and Prevention. (2023, October 25). Sickle Cell Disease. Retrieved from https://www.cdc.gov/ncbddd/sicklecell/facts.html

[3] GoodRx. (n.d.). Oxbryd Prices, Coupons & Patient Assistance Programs. Retrieved from https://www.goodrx.com/oxbryd